Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep Ensemble Learning to Detect Retinal Vascular Leakage on Ultrawide-Field Fundus Photographs of Patients With Uveitis.

Translational vision science & technology·2026
Same author

Racial Disparities Associated with Non-Infectious Anterior Uveitis and Concurrent Ocular Conditions: Results from a Large Multi-Institutional Research Network.

Ocular immunology and inflammation·2026
Same author

Gut microbial interaction networks control autoimmunity to neuroretina.

bioRxiv : the preprint server for biology·2026
Same author

Long-term management of recurrent uveitis associated with autoimmune lymphoproliferative syndrome.

Journal of ophthalmic inflammation and infection·2025
Same author

The Rate of Failure of Trabeculectomy and Tube Shunt Surgery in Eyes with Uveitic Glaucoma and Ocular Hypertension.

Ophthalmology. Glaucoma·2025
Same author

Effectiveness of Frequently Used TNF Inhibitors vs. Conventional Immunosuppressive Therapies for Noninfectious Uveitis.

Ocular immunology and inflammation·2025
Same journal

σ<sub>1</sub> receptor agonists: the new trend or an emerging therapeutic option?

Expert opinion on emerging drugs·2026
Same journal

Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Expert opinion on emerging drugs·2026
Same journal

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.

Expert opinion on emerging drugs·2026
Same journal

Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond.

Expert opinion on emerging drugs·2026
Same journal

Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.

Expert opinion on emerging drugs·2026
Same journal

Acute management of adult MOG antibody-associated disease: therapeutic choices and clinical outcomes.

Expert opinion on emerging drugs·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Emerging drugs for uveitis.

Theresa Larson1, Robert B Nussenblatt, H Nida Sen

  • 1National Eye Institute, National Institutes of Health, Bethesda, MD, USA. larsonta@nei.nih.gov

Expert Opinion on Emerging Drugs
|January 8, 2011
PubMed
Summary
This summary is machine-generated.

Uveitis treatments are advancing, moving from corticosteroids to steroid-sparing agents like biologics. Future therapies aim for targeted treatments with fewer side effects by understanding autoimmune disease mechanisms.

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Uveitis encompasses diverse infectious and noninfectious ocular inflammatory conditions.
  • Current uveitis treatment is limited by a lack of robust clinical trials comparing therapeutic efficacy.

Purpose of the Study:

  • To review current and future treatment strategies for uveitis.
  • To provide an understanding of corticosteroid and steroid-sparing agents in uveitis management.

Main Methods:

  • Literature search of PubMed (1965-2010) focusing on ocular inflammation treatments.
  • Emphasis on recent, large-scale studies and drug classes including corticosteroids, antimetabolites, calcineurin inhibitors, alkylating agents, and biologics.

Main Results:

  • Current strategies involve corticosteroids and a range of steroid-sparing agents.
  • Steroid-sparing agents include antimetabolites (methotrexate, azathioprine, mycophenolate mofetil), calcineurin inhibitors (cyclosporine, tacrolimus), alkylating agents (cyclophosphamide, chlorambucil), and biologics (TNF-α inhibitors, daclizumab, IFN-α(2a), rituximab).

Conclusions:

  • Emerging uveitis treatments are derived from existing drugs and immunological advancements.
  • Future treatments necessitate a deeper understanding of autoimmune mechanisms and improved drug delivery systems for targeted therapy with reduced adverse effects.